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Psoriasis is a chronic immune disorder that aﬀects 2–3% of the US population. Ustekinumab, a monoclonal antibody against IL-23/12,
has shown great eﬃcacy in treating psoriasis. Here we present a rare ﬁnding of a patient with plaque-type psoriasis who was diagnosed
with congestive heart failure after initiating treatment with ustekinumab. The patient experienced full recovery of cardiac function upon
discontinuation of ustekinumab.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psoriasis is a chronic, immune disorder that presents as
erythematous, indurated, and scaly plaques. The develop-
ments of biologic agents that target inﬂammatory cytoki-
nes have provided eﬀective and convenient treatment
options for the management of moderate-to-severe pla-
que-type psoriasis. Ustekinumab is a monoclonal antibody
against interluekin-12/23 cytokines that has proven highly
eﬃcacious in achieving clearance of psoriasis, with an
impressive safety proﬁle thus far based on worldwide usehttp://dx.doi.org/10.1016/j.jdds.2015.03.003
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Peer review under responsibility of King Saud University.for approximately 8 years. We report a case of a patient
with plaque-type psoriasis who experienced heart failure
following the initiation of ustekinumab therapy with full
recovery of cardiac function upon discontinuation of
ustekinumab.
2. Report of a case
A 46-year-old Hispanic female was diagnosed with
psoriasis and psoriatic arthritis in 2006. Treatment was
initiated with oral methotrexate once weekly and adali-
mumab biweekly. The patient experienced a generalized
desquamating rash that was attributed to the initiation of
adalimumab, which was discontinued promptly. The
patient was then started on etanercept and continued ther-
apy for 5 months until she developed a persistent cough
and fatigue. Workup with chest X-ray showed mediastinal
widening, and subsequent biopsy revealed non-Hodgkin
lymphoma. She received 6 cycles of R-CHOP
(Rituximab, Cyclophosphamide, Hydroxydaunorubicin,
Oncovin, Prednisone), with successful induction of remis-
sion based on PET scan ﬁndings.ehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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the patient resumed methotrexate therapy for her psoriasis.
After failure to improve on multiple trials of methotrexate,
prednisone, and rituximab, the patient was started on
ustekinumab in 2012. She initially noticed improvement
in her psoriasis, but this was accompanied by gradual wor-
sening shortness of breath and bilateral lower extremity
edema. Workup with echocardiography conﬁrmed a
diagnosis of congestive heart failure (CHF). Ustekinumab
was promptly discontinued, and the patient was started
on ACE-inhibitor and beta-blocker therapy, resulting in
the complete resolution of all her symptoms.3. Discussion
CHF is marked by progressive deterioration of cardiac
function, driven in part by a cascade of pro-inﬂammatory
cytokines and neuro-hormones (Sinagra et al., 2013). One
notable immune mediator with increased serum levels in
patients with CHF is TNF-alpha (Testa et al., 1996).
However, randomized, controlled trials with inﬂiximab
have shown that anti-TNF-alpha is associated with a wor-
sening of CHF (Chung et al., 2003). Analysis of data from
the US FDA Medwatch program revealed a total of 47
patients who developed new-onset heart failure following
the initiation of anti-TNF-alpha therapy (Kwon et al.,
2003). As a result, the labels of currently available anti-
TNF-alpha medications, including etanercept, inﬂiximab,
and adalimumab, caution against the use of these agents
in patients with heart failure or decreased left ventricular
function (Sinagra et al., 2013).
Ustekinumab is a monoclonal antibody within the class
of interleukin (IL)-12/23 inhibitors, which are novel bio-
logic treatment modalities for psoriasis that have proven
highly eﬃcacious in randomized controlled trials
(Famenini and Wu, 2013; Gordon et al., 2012; Kimball
et al., 2012). However, many of the studies that have exam-
ined the cardiovascular risk proﬁle of ustekinumab have
speciﬁed a history of heart failure as an exclusion criterion.
Thus, there are scant data from these clinical trials about
the relationship between ustekinumab therapy and heart
failure. Long-term post-marketing surveillance has pro-
vided an additional avenue for determining the association
between ustekinumab and rare potential adverse events.
The EUV database with 1394 total events includes 16 cases
of heart failure (Ustekinumab (Stelara), 2013).
Although neither the present case nor data from post-
marketing surveillance establishes an unequivocal cause–
eﬀect relationship between ustekinumab and heart failure,
both may constitute a signal that supports further
investigation into this association. Particularly pertinent
in this case is the temporal relationship between the initia-
tion of ustekinumab therapy and the onset of heart failure.
The patient’s improvement with the cessation of this med-
ication is also supportive, though concurrent beta-blocker
and ACE-inhibitor therapy may have contributed to herrecovery as well. Furthermore, the patient had no previous
history of cardiovascular abnormalities prior to this event.
Other potential causes of CHF in this patient include
prior exposure to doxorubicin as a part of her chemother-
apy regimen. Doxorubicin-induced cardiomyopathy may
occur in as many as a third of patients. However, the
majority of cases occur within 1 year of discontinuing the
medication, with rare instances of late-onset doxorubicin-
induced cardiomyopathy, which arises more than 1 year
after the completion of chemotherapy, occurring predomi-
nantly in pediatric populations (Aiken et al., 2009;
Chatterjee et al., 2010; Lipshultz et al., 2008). The onset
of CHF in this patient took place over 5 years following
the completion of her chemotherapy, making this a less
likely cause of her condition.
Additionally, this patient was diagnosed with lymphoma
prior to experiencing heart failure. In rare cases, lymphoma
has been associated with heart failure secondary to metas-
tasis to cardiac tissue (Amirimoghaddam et al., 2010).
However, heart metastases from lymphoma are remarkably
uncommon, with only a few reported cases worldwide.
Furthermore, multiple MRI studies performed on this
patient during routine surveillance for recurrence of her
lymphoma gave no indication of heart metastases.
The mechanistic relationship between anti-IL-12/23
agents and cardiac adverse events such as CHF has yet
to be elucidated. We propose the mechanism to be
immune-mediated, with potential interactions with the
pathway through which TNF-alpha aﬀects cardiac tissue.
In light of this potential association, it is essential that
physicians take precautions when prescribing ustekinumab
for the treatment of psoriasis in patients with a personal or
family history of heart disease. We recommend a thorough
screening for cardiomyopathy prior to the initiation of
therapy in patients with a personal or family history of
heart disease, and a complete cardiac evaluation of patients
on ustekinumab who report alarming symptoms such as
chest pain or shortness of breath.
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